ACKR3 and depressive symptom measurement: After preincubation with 0.0625, 0.125, 0.25, 0.5, and 1 mg/mL XKS, we found that in vitro XKS treatment led to an increase of CXCR7 level in the EPCs from CAD patients with anxiety/depression, particularly at 0.5 mg/mL (P < 0.01) (Figures 5(a) and 5(b)).